Related Experiment Video
Updated: Aug 30, 2026

In vivo Imaging Method to Distinguish Acute and Chronic Inflammation
Published on: August 16, 2013
[Inflammation markers in daily practice]
F Le Roy1, S Barbier, E Martin Passos
1Service de néphrologie, Centre hospitalier universitaire de Rouen. Frank.Le-Roy@chu-rouen.fr
Insights
Inflammation markers like C-reactive protein and procalcitonin can help manage hemodialysis patients by predicting mortality and detecting infections. Early detection improves patient outcomes and treatment strategies.
Area of Science:
- Nephrology
- Clinical Chemistry
- Infectious Diseases
Background:
- Cardiovascular diseases and infections are leading causes of mortality in End-Stage Renal Disease (ESRD) patients.
- European guidelines recommend using inflammation markers in daily hemodialysis practice.
- These markers predict cardiovascular and overall mortality and aid in detecting silent infections.
Purpose of the Study:
- To highlight the importance of inflammation markers in managing ESRD patients undergoing hemodialysis.
- To emphasize the role of C-reactive protein and procalcitonin in improving diagnostic and therapeutic strategies.
Main Methods:
- Review of current clinical practice and recommendations in hemodialysis.
- Discussion of the utility of C-reactive protein as a general inflammation marker.
- Emphasis on the specific role of procalcitonin in identifying bacterial infections.
Main Results:
- Inflammation markers effectively predict mortality in ESRD patients.
- These markers assist in identifying subclinical infections (e.g., parodontitis, H. pylori, shunt infections).
- Inflammation markers contribute to assessing dialysis biocompatibility.
Conclusions:
- Combining C-reactive protein and procalcitonin measurements can enhance diagnostic and therapeutic strategies for hemodialysis patients.
- Routine monitoring of inflammation markers is crucial for improving patient care and outcomes in ESRD.
Abstract:
Cardiovascular diseases and infections remain the first mortality causes in ESRD patients. European recommendations for good clinical practice in the hemodialysis field advocate to use the inflammation markers in daily practice. These markers foretell both cardiovascular and global mortality. They also enable to detect the silent infections (parodontitis, Heliobacter pilory infection, shunt infection in PTFE), to make sure of the dialysis biocompatibility (microbiological quality of the dialysate, use of biocompatible membrane). The C-reactive protein is the most current and used marker. Its use, combined with the procalcitonin measurement, specific marker for bacterial infection, would enable the diagnostic and therapeutic strategy improvement.
Related Concept Videos
Inflammation: Introduction
Acute Inflammation I: Inflammatory Response
Acute Inflammation III: Local and Systemic Effects
Chronic Inflammation: Introduction
Inflammatory Response I: Vascular and Cellular
Inflammation

